Cost of Praluent PCSK9 Inhibitor Lowered for Medicare Patients

The cost of Praluent, regardless of dose, will be $5,850 annually, a 60% reduction from the original price.

FEBRUARY 12, 2019

Amgen Wins Next Step in Patent Dance Over PCSK9 Drugs

Despite the win, the case is long from over; Sanofi and Regeneron plan to appeal.

MARCH 24, 2016